Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Health
First Opinion
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Politics
STAT+

Here’s where Democrats’ resurrected drug pricing talks are headed

  • Nicholas Florko
  • Rachel Cohrs

By Nicholas Florko and Rachel Cohrs Nov. 2, 2021

Reprints
D.C. Insight IMAGE
Alex Hogan/STAT

You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

Where Democrats’ resurrected drug pricing talks are headed

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Nicholas Florko

Nicholas Florko

Washington Correspondent

Nicholas Florko reports on the the intersection of politics and health policy. He is the author the newsletter "D.C. Diagnosis."

Rachel Cohrs

Rachel Cohrs

Washington Correspondent

Rachel reports on the intersection of politics and health policy.

Tags

Create a display name to comment

This name will appear with your comment

Trending
CDC_MONKEYPOX
EU health agency warns monkeypox could become endemic in…
EU health agency warns monkeypox could become endemic in Europe if outbreak continues
Monkeypox
A CDC expert answers questions on monkeypox
A CDC expert answers questions on monkeypox
CDC_MONKEYPOX
U.S. monkeypox case reported, as Spain, Portugal report infections…
U.S. monkeypox case reported, as Spain, Portugal report infections in growing outbreak
Recommended
Pharmalittle: Cancer coalition aims to boost access to meds…
Pharmalittle: Cancer coalition aims to boost access to meds in poor countries; Moderna’s vaccine patent defense…
Listen: Mysterious infections, dwindling Covid funds, & Shkreli out…
Listen: Mysterious infections, dwindling Covid funds, & Shkreli out of prison
AstraZeneca building
AstraZeneca’s ambitious vaccine dreams are finally, officially dead
AstraZeneca’s ambitious vaccine dreams are finally, officially dead

Recommended Stories

OrigamiBoats_Illustration_MollyFerguson_051822
A STAT Investigation

How a complex web of businesses turned private health records from GE into a lucrative portrait of patients

By Casey Ross

pills
Pharmalot

European regulator suspends generic drugs after finding flawed studies

By Ed Silverman

assisted living_walker
Insurance

Former top Medicare official says Medicare Advantage’s coding industry offers ‘no benefit to society’

By Bob Herman

Blue inhaler
Pharmalot

Drugmakers use monopoly tactics to thwart lower-cost generic competition for inhalers, analysis finds

By Ed Silverman

BiotechClawMachine_Illustration_MollyFerguson_051122
Biotech

When biotech acquisitions spike, early-stage startups are prime targets, analysis shows

By Kate Sheridan